Your World, Fully Explored.

Published 6 days ago • loading... • Updated 6 days ago

Illuccix China Phase 3 Study Completes Enrolment

Summary by Macau Business

MELBOURNE, Australia and INDIANAPOLIS, May 13, 2025 /PRNewswire/ — Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”, “the Company”) today announces that the pivotal Phase 3 registration study of TLX591-CDx (Illuccix®, Kit for the preparation of 68Ga-PSMA-11) for prostate cancer imaging in Chinese patients has completed patient enrolment. The Phase 3 Illuccix China study[1] is a prospective, open-label, single-arm, multicenter study…

This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.

3 Articles

3 Articles

All

Left

Center

Right

+2 Reposted by 2 other sources

Illuccix China Phase 3 Study Completes Enrolment

MELBOURNE, Australia and INDIANAPOLIS, May 13, 2025 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, "Telix", "the

6 days ago

Read Full Article

Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/year

Coverage Details

Total News Sources3

Leaning Left0Leaning Right0Center0Last Updated6 days agoBias Distribution

No sources with tracked biases.

Bias Distribution

There is no tracked Bias information for the sources covering this story.

Untracked bias

Factuality

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

FNArena broke the news in 6 days ago on Monday, May 12, 2025.

Sources are mostly out of (0)

Similar News Topics

Similar News Topics